Optive Brand For Day And Night Dry Eye Management
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2019-06-20
- Lead Sponsor
- Allergan
- Target Recruit Count
- 35
- Registration Number
- NCT03208673
- Locations
- 🇬🇧
Ocular Technology Group - international, London, United Kingdom
Long Term Prospective Uncontrolled Study Of Earfold™ For The Treatment Of Prominent Ears
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Allergan
- Target Recruit Count
- 84
- Registration Number
- NCT03194269
- Locations
- 🇬🇧
Sthetix /ID# 233668, Liverpool, United Kingdom
🇬🇧Medcentres Plus /ID# 233687, Salisbury, United Kingdom
🇬🇧University Hospital of Derby and Burton NHS Foundation Trust /ID# 233610, Derby, Derbyshire, United Kingdom
BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine
- Conditions
- Interventions
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2017-07-14
- Lead Sponsor
- Allergan
- Registration Number
- NCT03193346
Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2017-07-14
- Lead Sponsor
- Allergan
- Registration Number
- NCT03193359
Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Correction of Temple Hollowing
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1
- Registration Number
- NCT03166618
- Locations
- 🇺🇸
Skin Care and Laser Physicians of Beverly Hills, Los Angeles, California, United States
Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1
- Registration Number
- NCT03091439
- Locations
- 🇺🇸
Midway Immunology and Research Center, Fort Pierce, Florida, United States
Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence
- Conditions
- Interventions
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2019-12-24
- Lead Sponsor
- Allergan
- Target Recruit Count
- 120
- Registration Number
- NCT03052764
- Locations
- 🇺🇸
Urology Clinics of North Texas, Dallas, Texas, United States
🇺🇸Adult and Pediatric Urology, Omaha, Nebraska, United States
🇺🇸Regional Urology, Shreveport, Louisiana, United States
Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Allergan
- Target Recruit Count
- 420
- Registration Number
- NCT03043287
- Locations
- 🇺🇸
Regional Urology, Shreveport, Louisiana, United States
🇺🇸Chesapeake Urology Associates, LLC, Baltimore, Maryland, United States
🇺🇸Virginia Urology, Richmond, Virginia, United States
Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME)
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Allergan
- Target Recruit Count
- 115
- Registration Number
- NCT03003416
- Locations
- 🇫🇷
CHU Brest, Brest, France
🇫🇷CHU Pasteur 2, Nice, France
🇫🇷CHU Bordeaux, Bordeaux, France
A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT®™ With Lidocaine for Dynamic Radial Cheek Line Skin Depressions
- Conditions
- Interventions
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Allergan
- Target Recruit Count
- 53
- Registration Number
- NCT02980783
- Locations
- 🇫🇷
Laboratoire DERMSCAN, Lyon, France